武汉华康世纪洁净科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 武汉华康世纪洁净科技股份有限公司（以下简称"公司"）于 2024 年 11 月 5 日召开第二届董事会第十九次会议、第二届监事会第十八次会议，于 2024 年 11 月 21 日召开 2024 年第五次临时股东大会，审议通过《关于回购公司股份方 案的议案》，公司将使用自有资金及自筹资金（含回购专项贷款资金）以集中竞 价交易方式回购部分公司已在境内发行上市人民币普通股（A 股）股票，用于实 施员工持股计划或股权激励计划。 本次回购股份的资金总额不低于人民币 5,000 万元（含），不超过人民币 7,000 万元（含），回购股份的价格不超过 28.00 元/股（含本数）。具体回购数 量以回购期限届满时实际回购的股份数量为准。本次回购的实施期限为自公司股 东大会审议通过回购方案之日起 12 个月内。具体内容详见公司于 2024 年 11 月 6 日、2024 年 11 月 22 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于回 购公司股份方 ...

证券代码：301235 证券简称：华康洁净 公告编号：2025-067 转债代码：123251 转债简称：华医转债 武汉华康世纪洁净科技股份有限公司 关于项目预中标的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示：本项目仍处于中标公示阶段，其获取中标通知书、签约等后续工 作尚具有一定不确定性，敬请广大投资者注意投资风险。武汉华康世纪洁净科技 股份有限公司（以下简称"公司"）将根据相关事项后续进展情况履行相应的信 息披露义务。 公司于近日参与了"重庆市第十三人民医院蔡家院区建设一期工程医疗专项 及设备采购安装工程"的投标，招标单位为重庆市第十三人民医院(项目业主)、 重庆市工程管理有限公司(代理业主)。2025 年 5 月 30 日，重庆市公共资源交易 网（https://www.cqggzy.com/）发布了相关中标候选人公示。现将具体预中标 情况提示如下： 一、预中标项目概况 1、招标单位名称：重庆市第十三人民医院(项目业主)、重庆市工程管理有 限公司(代理业主) 2、招标代理机构名称：中航技国际经贸发展有限公司 3、项目标段名称：重庆 ...

Group 1 - China Energy Construction won a major coal-fired power project with a bid amount of approximately 14.586 billion yuan, involving six 660 MW supercritical coal-fired generating units and supporting environmental facilities, with a total construction period of about 36.5 months [1] - Taiji Industry plans to repurchase company shares with a total amount not less than 1 billion yuan and not exceeding 1.2 billion yuan, with a maximum repurchase price of 10.38 yuan per share [1] - Youxun Technology won a project from State Grid with a bid amount of approximately 176 million yuan, accounting for 17.44% of the company's audited revenue for 2024 [2] Group 2 - Daili New Materials established an investment fund with a total subscribed capital of 163.3 million yuan, with Daili contributing 10 million yuan, accounting for 6.12% of the fund [4] - Wanyi Technology received a government subsidy of 2.3475 million yuan, which has been confirmed and classified according to relevant accounting standards [6] - Anke Biotech received a drug registration certificate for Acetate Atosiban Injection, which is used for treating preterm labor [7] Group 3 - Renfu Pharmaceutical received a drug registration certificate for Progesterone Soft Capsules, which are used to treat functional disorders caused by progesterone deficiency [9] - Linyang Energy is a recommended candidate for a major contract with State Grid, with a total expected bid amount of approximately 165 million yuan [11] - Hongtian Technology plans to invest 200 million to 300 million yuan to establish a wholly-owned subsidiary in Gansu Province [28] Group 4 - Hunan Xiang Electric received a total of 40 million yuan in government subsidies, which accounts for 16.07% of the company's audited net profit for 2024 [44] - Nengke Technology plans to repurchase shares with a total amount not less than 10 million yuan and not exceeding 20 million yuan, with a maximum repurchase price of 43.00 yuan per share [46] - Xiamen XGMA received 10 million yuan in historical debt repayment, which is expected to increase the company's net profit for 2025 by 3.186 million yuan [48]

一、中标项目基本情况 1、建设规模：对四川大学华西医院第二住院楼 10 层至 13 层进行统一装修 规划，布局 48 间手术室，建筑面积约 10,000 平方米，项目投资额 8,200 万元。 2、建设地点：四川省成都市武侯区国学巷 37 号，四川大学华西医院院区内。 3、中标范围：详见项目施工图、技术要求及工程量清单所示的全部施工内 容。 4、中标价：71,602,160.12 元 5、工期：365 日历天 6、工程质量：①施工质量符合设计图纸及国家有关标准、规范要求，工程 质量达到国家及行业现行施工验收规范合格标准；②项目所有材料、设备采购质 量需符合设计图纸及有关标准、规范的要求；符合发包人对上述设备、材料的品 牌、型号、规格、产地的具体要求。 证券代码：301235 证券简称：华康洁净 公告编号：2025-066 转债代码：123251 转债简称：华医转债 武汉华康世纪洁净科技股份有限公司 关于收到中标通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 武汉华康世纪洁净科技股份有限公司（以下简称"公司"）于 2025 年 5 月 19 日在创 ...

公司于近日参与了"湖北省县域医共体设备标准化和提质升级项目"的投标， 招标单位为湖北省卫生健康委员会。2025 年 5 月 27 日，中国政府采购网（http s://www.ccgp.gov.cn）发布了相关中标结果公告。现将具体预中标情况提示如 下： 证券代码：301235 证券简称：华康洁净 公告编号：2025-065 转债代码：123251 转债简称：华医转债 武汉华康世纪洁净科技股份有限公司 关于项目预中标的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示：本项目仍处于中标公示阶段，其获取中标通知书、签约等后续工 作尚具有一定不确定性，敬请广大投资者注意投资风险。武汉华康世纪洁净科技 股份有限公司（以下简称"公司"）将根据相关事项后续进展情况履行相应的信 息披露义务。 一、预中标项目概况 1、采购人名称：湖北省卫生健康委员会 2、采购代理机构名称：湖北省成套招标股份有限公司 3、中标名称：湖北省县域医共体设备标准化和提质升级项目二标包 二、预中标事项对公司业绩的影响 该项目为医疗设备采购业务，中标后的实施预计对公司未来经营业绩产生 ...

华康洁净（301235）公告，公司收到中标通知书，与中元建设集团组成的联合体中标"嘉兴市第二医院 整体迁建项目净化及实验室工程"，中标金额为1.67亿元。公司预计份额为1.33亿元，占公司2024年度经 审计营业收入的7.81%。项目总建筑面积46.13万平方米，最高洁净等级为百级，工期为260个日历天。 ...

1、建设规模：新建 17 层主体医疗楼，7 层行政科教楼及与它们连通的 2 层 地下室；新建污水处理站、垃圾处理站、液氧站等。同步实施道路广场、绿化、 室外管线等室外工程，设置机动车停车位 4,059 个；设置床位数 2,000 床。总建 筑面积 461,323.20 平方米，其中地上建筑面积 279,071.28 平方米，地下建筑面 积 182,251.92 平方米。本次净化及实验室的面积约为 25,265 平方米，最高洁净 等级为百级。 武汉华康世纪洁净科技股份有限公司 关于收到中标通知书的公告 | | | 武汉华康世纪洁净科技股份有限公司（以下简称"公司"）于 2025 年 4 月 30 日在创业板信息披露网站巨潮资讯网（www.cninfo.com.cn）上披露了《关于 项目预中标的提示性公告》（公告编号：2025-049）。近日，公司收到招标代理 机构嘉兴市建新工程造价咨询事务所有限公司发出的《中标通知书》，确认公司 与中元建设集团股份有限公司组成的联合体（以下简称"联合体"）为"嘉兴市 第二医院整体迁建(长三角国际医学中心总医院)项目(主体医疗楼、行政科教楼、 2 号地下室、2 号地下污水处理站、 ...

Investment Rating - The report initiates coverage with a "Neutral" rating for the company [3][4]. Core Insights - The company is a professional cleanroom system integration service provider, expanding its business from public hospital medical cleanrooms to high-level academic laboratories and industrial electronics [3][13]. - The cleanroom market in China is expected to exceed 500 billion yuan by 2032, with a compound annual growth rate (CAGR) of over 7% from 2023 to 2032 [31][36]. - The company has a strong position in the cleanroom industry, with a focus on electronic cleanrooms expected to become a significant growth driver [5][30]. Summary by Sections Company Overview - The company provides full-cycle services for cleanroom construction, including project consulting, planning, design, management, construction, system debugging, and maintenance [3][19]. Financial Performance - The company has maintained steady revenue growth, with a CAGR of 23.8% from 2017 to 2024, although profits have faced some pressure due to delayed payments [25][28]. - Revenue projections for 2024 to 2027 show significant growth, with expected revenues of 1,708 million yuan in 2024, increasing to 4,151 million yuan by 2027 [6][18]. Market Potential - The electronic cleanroom sector is anticipated to be the fastest-growing segment for the company, with the market size expected to reach 165.7 billion yuan in 2024 [31][39]. - The company is positioned in the first tier of the industry, with a strong competitive advantage due to its technical capabilities and marketing network [30][42]. Technological Advantages - The company has developed various core technologies in cleanroom systems, enhancing its ability to attract customers and expand into new application scenarios [51][52]. - The company has accumulated numerous patents in the cleanroom field, indicating a strong focus on innovation and technology development [52]. Government Relations and Order Acquisition - The company has established strong relationships with government entities, enhancing its order acquisition capabilities, particularly in the electronic cleanroom sector [53].

Market Performance - On May 23, major market indices experienced fluctuations and closed lower, with A-shares trading volume reaching 1.18 trillion yuan, and over 1,100 stocks closing higher, including 52 stocks hitting the daily limit [1] - For the week, the Shanghai Composite Index fell by 0.57%, the ChiNext Index dropped by 0.88%, and the STAR Market 50 Index decreased by 1.47% [1] Individual Stock Performance - Over 1,600 stocks rose this week, with 22 stocks gaining over 30%. Notably, six stocks surged over 50%, with the largest increase being 99.96% for Sanofi [1][2] - Other significant gainers included Huibo Yuntong (301316) and Binhai Energy (000695), both of which saw weekly increases exceeding 60% [1][2] Sector Analysis - Among the stocks that rose over 30%, the pharmaceutical and biological sector had six representatives, followed by light industry manufacturing with three stocks [1] Historical Highs - On May 23, 17 stocks reached historical closing highs, with the pharmaceutical and biological, mechanical equipment, and automotive sectors showing a concentration of high performers [3][4] - The average increase for stocks reaching historical highs was 8.20%, with notable gainers including Xintiandi (301277) and Zhongzhou Special Materials (300963) [3] Institutional Activity - On May 23, ten stocks saw net purchases from institutions, with Yixin Tang (002727) leading at a net buy of 102 million yuan [5][6] - Conversely, institutions sold off stocks such as Hongchuang Holdings (002379) and Tianqimo (002510), each experiencing net sales exceeding 50 million yuan [5][6] Northbound Capital Flow - Northbound capital was present in nine stocks on the trading board, with net purchases in three stocks: Xue Ren Shares (002639), Huibo Yuntong, and Jinlongyu (002882) [7] - Yixin Tang faced the highest net sell-off from northbound capital, totaling 68.98 million yuan [7] Company Announcements - Zhongjin Gold (600489) plans to inject four companies, including Inner Mongolia Jintao, into the company to resolve competition issues [8] - Huakang Clean (301235) won a bid for a healthcare project with a contract value of 60.24 million yuan and a duration of 120 days [8] - Weier Shares (603501) intends to issue H-shares and list on the Hong Kong Stock Exchange [9] - Yunchongma (603130) plans to raise no more than 640 million yuan for a project to produce DTY silk and high-performance leather base fabric [9]

Core Viewpoint - The company, originally established in 2008 as a leading cleanroom system integrator, is expanding its business from medical applications to laboratory integration and electronic cleanroom services, aiming to create a second growth curve and enhance its market position in the semiconductor ecosystem [1][2]. Group 1: Business Expansion and Market Position - The company has transitioned from focusing solely on medical cleanrooms to include laboratory integration and electronic cleanroom services, having served over 800 clients including public hospitals and industrial electronics firms [1]. - The company announced a name change from "Huakang Medical" to "Huakang Clean" in March 2025, and plans to issue 750 million yuan in convertible bonds to support new business initiatives [1]. - A joint venture named "Wuhan Guanggu Huafeng Operation Technology Co., Ltd." was established with partners to strengthen future growth in the cleanroom technology sector [1]. Group 2: Market Dynamics and Financial Performance - The medical purification system market in China is valued at approximately 31.27 billion yuan annually, with the company holding orders worth 2.753 billion yuan for 2024, indicating a robust order book [2]. - The company has achieved positive operating cash flow of 150 million yuan in 2024, indicating a balance between orders and cash flow, which supports sustainable growth in its core business [2]. - The electronic cleanroom sector, which accounted for 54% of the cleanroom industry in 2022, is expected to see continued demand growth, with the company entering this market through strategic partnerships and service capabilities [2]. Group 3: Revenue and Profit Forecast - Revenue projections for the company from 2025 to 2027 are estimated at 2.8 billion, 3.6 billion, and 4.8 billion yuan, representing year-on-year growth rates of 61%, 32%, and 33% respectively [3]. - The net profit attributable to the parent company is forecasted to be 170 million, 220 million, and 300 million yuan for the same period, with growth rates of 156%, 30%, and 35% respectively [3]. - The company is expected to maintain a solid growth trajectory based on its established experience in the medical cleanroom sector and its expansion into the semiconductor cleanroom market [3].